Field defects in progression to gastrointestinal tract cancers

Cancer Letters

Volumn 260, Issue 1-2, 2008, Pages 1-10

  Bernstein, Carol ^a,d   Bernstein, Harris ^a,c   Payne, Claire M ^a,c   Dvorak, Katerina ^a,c,d   Garewal, Harinder ^b,c,d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Cancer progression; Field defect; Field of cancerization; Gastrointestinal cancer; Pre malignant; Tumorigenesis

Indexed keywords

BILE ACID; DNA; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN BCL XL; SURVIVIN;

ADENOMATOUS POLYP; APOPTOSIS; BARRETT ESOPHAGUS; BILE DUCT CANCER; CANCER RISK; CELL PROLIFERATION; COLON CARCINOGENESIS; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; ESOPHAGUS CANCER; HEAD AND NECK CARCINOMA; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; LARYNX CANCER; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; OROPHARYNX CANCER; PANCREAS CANCER; PRECANCER; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SECOND CANCER; SHORT SURVEY; SMALL INTESTINE CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS; TREATMENT FAILURE; TUMOR CELL; ULCERATIVE COLITIS;

EID: 38349026288     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.11.027     Document Type: Review

References (69)

1. C. Bernstein, H. Bernstein, C.M. Payne, H. Garewal. Field defects in progression to adenocarcinoma of the colon and esophagus. Electron. J. Biotechnol. (2000). Available from: .
2. Baylin S.B., and Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction. Nature Rev./Cancer 6 (2006) 107-116
3. Bielas J.H., Loeb K.R., Rubin B.P., True L.D., and Loeb L.A. Human cancers express a mutator phenotype. Proc. Natl. Acad. Sci. USA 103 (2006) 18238-18242
4. Cianfriglia F., Di Gregorio D.A., and Manieri A. Multiple primary tumours in patients with oral squamous cell carcinoma. Oral Oncol. 35 (1999) 157-163
5. Dhooge I.J., De Vos M., and Van Cauwenberge P.B. Multiple primary malignant tumors in patients with head and neck cancer: Results of a prospective study and future perspectives. Laryngoscope 108 (1998) 250-256
6. Partridge M., Pateromichelakis S., Phillips E., Emilion G.G., A'Hern R.P., and Langdon J.D. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res. 60 (2000) 3893-3898
7. Tabor M.P., Braakhuis B.J.M., van der Wal J.E., van Diest P.J., Leemans C.R., Brakenhoff R.H., and Kummer J.A. Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. J. Pathol. 199 (2003) 354-360
8. Monique G., van Oijen C.T., and Slootweg P.J. Oral field cancerization: Carcinogen-induced independent events or micrometastatic deposits?. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 249-256
9. Braakhuis B.J.M., Tabor M.P., Kummer J.A., Leemans C.R., and Brakenhoff R.H. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 63 (2003) 1727-1730
10. Schepman K.P., van der Meij E.H., Smeele L.E., and van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from the Netherlands. Oral Oncol. 34 (1998) 270-275
11. Ling F.C., Baldus S.E., Khochfar J., Xi H., Neiss S., Brabender J., Metzger R., Dreber U., Dienes H.P., Bollschweiler E., Hoelscher A.H., and Schneider P.M. Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer. Histopathology 50 (2007) 203-209
12. Nehra D., Howell P., Williams C.P., Pye J.K., and Beynon J. Toxic bile acids in gastrooesophageal reflux disease: influence of gastric acidity. Gut 44 (1999) 598-602
13. Bernstein H., Bernstein C., Payne C.M., Dvorakova K., and Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat. Res. 589 (2005) 47-65
14. Dvorakova K., Payne C.M., Ramsey L., Bernstein H., Holubec H., Chavarria M., Bernstein C., Sampliner R.E., Riley C., Prasad A., and Garewal H. Apoptosis resistance in Barrett's esophagus: ex vivo bioassay of live stressed tissues. Am. J. Gastroenterol. 100 (2005) 424-431
15. Dvorakova K., Payne C.M., Ramsey L., Holubec H., Sampliner R., Dominguez J., Dvorak B., Bernstein H., Bernstein C., Prasad A., Fass R., Cui H., and Garewal H. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin. Cancer Res. 10 (2004) 2020-2028
16. Maley C.C. Multistage carcinogenesis in Barrett's esophagus. Cancer Lett. 245 (2007) 22-32
17. Bian Y.S., Osterheld M.C., Bosman F.T., Benhattar J., and Fontolliet C. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod. Pathol. 14 (2001) 397-403
18. Garewal H.S., Sampliner R., Liu Y., and Trent J. Chromosomal rearrangements in Barrett's esophagus. A premalignant lesion of esophageal adenocarcinoma. Cancer Genet. Cytogenet. 42 (1989) 281-296
19. Lai L.A., Paulson T.G., Li X., Sanchez C.A., Maley C., Odze R.D., Reid B.J., and Rabinovitch P.S. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes, Chromosomes Cancer 46 (2007) 532-542
20. Koppert L.B., Wijnhoven B.P.L., Van Dekken H., Tilanus H.W., and Dinjens W. The molecular biology of esophageal adenocarcinoma. J. Surg. Oncol. 92 (2005) 169-190
21. Feith M., Stein H.J., Mueller J., and Siewert J.R. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. Dis. Esophagus 17 (2004) 322-327
22. Brabender J., Marjoram P., Lord R.V.N., Metzger R., Salonga D., Vallbohmer D., Schafer H., Danenberg K.D., Danenberg P.V., Selaru F.M., Baldus S.E., Holscher A.H., Meltzer S.J., and Schneider P.M. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 2113-2117
23. Freedman N.D., Abnet C.C., Leitzmann M.F., Mouw T., Subar A.F., Hollenbeck A.R., and Schatzkin A. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am. J. Epidemiol. 165 (2007) 1424-1433
24. Tian D., Feng Z., Hanley N.M., Setzeer R.W., Mumford J.L., and DeMarini D.M. Multifocal accumulation of p53 protein in esophageal carcinoma: evidence for field cancerization. Int. J. Cancer 78 (1998) 568-575
25. Crew K.D., and Neugut A.I. Epidemiology of gastric cancer. World J. Gastroenterol. 12 (2006) 354-362
26. Ye W., Chow W.H., Lagergren J., Yiin L., and Nyren O. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 121 (2001) 1286-1293
27. Ushijima T., Nakajima T., and Maekita T. DNA methylation as a marker for the past and future. J. Gastroenterol. 41 (2006) 401-407
28. Nakajima T., Maekita T., Oda I., Gotoda T., Yamamoto S., Umemura S., Ichinose M., Sugimura T., Ushijima T., and Saito D. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol. Biomarkers. Prev. 15 (2006) 2317-2321
29. Ang K.L., Shi D.L., Keong W.W., and Epstein R.J. Upregulated Akt signaling adjacent to gastric cancers: implications for screening and chemoprevention. Cancer Lett. 225 (2005) 53-59
30. Kuwahara A., Saito T., and Kobayashi M. Bile acids promote carcinogenesis in the remnant stomach of rats. J. Cancer Res. Clin. Oncol. 115 (1989) 423-428
31. Kondo K. Duodenogastric reflux and gastric stump carcinoma. Gastric Cancer 5 (2002) 16-22
32. Crow S.E. Helicobacter infection, chronic inflammation, and the development of malignancy. Curr. Opin. Gastroenterol. 21 (2005) 32-38
33. Lochhead P., and El-Omar E.M. Helicobacter pylori infection and gastric cancer. Best Pract. Res. Clin. Gastroenterol. 21 (2007) 281-297
34. Farinati F., Cardin R., Russo V.M., Busatto G., and Franco M. Helicobacter pylori CagA status, mucosal oxidative damage and gastritis phenotype: A potential pathway to cancer?. Helicobacter 8 (2003) 227-234
35. El-Omar E.M., Carrington M., Chow W.H., McColl E.E.L., Bream J.H., Young H.A., Herrera J., Lissowska J., Yuan C.C., Rothman N., Lanyon G., Martin M., Fraumeni Jr. J.F., and Rabkin C.S. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404 (2000) 398-402
36. Goodman Z.D. Neoplasms of the liver. Modern Pathol. 20 (2007) S49-S60
37. Boberg K.M., Bergquist A., Mitchell S., Pares A., Rosina F., Broome U., Chapman R., Fausa O., Egeland T., Rocca G., and Schrumpf E. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand. J. Gastroenterol. 37 (2002) 205-211
38. Kobayashi S., Werneburg N.W., Bronk S.F., Kaufmann S.H., and Gores G.J. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128 (2005) 2054-2065
39. Fischer H.P., and Zhou H. Pathogenesis of carcinoma of the papilla of Vater. J. Hepatobiliary Pancreat. Surg. 11 (2004) 301-309
40. Greten F.R., Weber C.K., Greten T.F., Schneider G., Wagner M., Adler G., and Schmid R.M. Stat3 and NF-κB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123 (2002) 2052-2063
41. Tucker O.N., Dannenberg A.J., Yang E.K., and Jahey III T.J. Bile acids induce cyclooxygnase-2 expression in human pancreatic cancer cell lines. Carcinogenesis 25 (2004) 419-423
42. Payne C.M., Bernstein H., Bernstein C., and Garewal H. Role of apoptosis in biology and pathology: resistance to apoptosis in colon carcinogenesis. Ultrastruct. Pathol. 19 (1995) 221-248
43. Izawa T., Obara T., Tanno S., Mizukami Y., Yanagawa N., and Kohgo Y. Clonality and field cancerization in intraductal papillary-mucinous tumors of the pancreas. Cancer 92 (2001) 1807-1817
44. Ross R.K., Hartnett N.M., Bernstein L., and Henderson B.E. Epidemiology of adenocarcinomas of the small intestine: is bile a small bowel carcinogen?. Br. J. Cancer 63 (1991) 143-145
45. Jagelman D.G., DeCosse J.J., and Bussey H.J.R. The Leeds Castle Polyposis Group. Upper gastrointestinal cancer in familial adenomatous polyposis. The Lancet 1 (1988) 1149-1151
46. Spigelman A.D., Williams C.B., Talbot I.C., Domizio P., and Phillips R.K.S. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. The Lancet 2 (1989) 783-785
47. Polley A.C.J., Mulholland F., Pin C., Williams E.A., Bradburn M.D., Mills S.J., Mathers J.C., and Johnson I.T. Proteomic analysis reveals field-wide changes in protein expression in the morphologically normal mucosa of patients with colorectal neoplasia. Cancer Res. 66 (2006) 6553-6562
48. Hao C.Y., Moore D.H., Wong P., Bennington J.L., Lee N.M., and Chen L.C. Alteration of gene expression in macroscopically normal colonic mucosa from individuals with a family history of sporadic colon cancer. Clin. Cancer Res. 11 (2005) 1400-1407
49. min mice and human cancer patients. Cancer Res. 64 (2004) 3694-3700
50. Shen L., Kondo Y., Rosner G.L., Xiao L., Hernandez N.S., Vilaythong J., Houlihan P.S., Krouse R.S., Prasad A.R., Einspahr J.G., Buckmeier J., Alberts D.S., Hamilton S.R., and Issa J.P. MGMT promoter methylation and field defect in sporadic colorectal cancer. J. Natl. Cancer Inst. 97 (2005) 1330-1338
51. Anti M., Armuzzi A., Morini S., Iascone E., Pignataro G., Coco C., Lorenzetti R., Paolucci M., Covino M., Gasbarrini A., Vecchio F., and Gasbarrini G. Severe imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract in subjects with a history of large adenomas. Gut 48 (2001) 238-246
52. Hutchins J.T., Reading C.L., Giavazzi R., Hoaglund J., and Jessup J.M. Distribution of mono-, di, and tri-O-acetylated sialic acids in normal and neoplastic colon. Cancer Res. 48 (1988) 483-489
53. Badvie S., Hanna-Morris A., Andreyev H.J.N., Cohen P., Saini S., and Allen-Mersh T.G. A "field change" of inhibited apoptosis occurs in colorectal mucosa adjacent to colorectal adenocarcinoma. J. Clin. Pathol. 59 (2006) 942-946
54. Bronner M.P., Culin C., Reed J.C., and Furth E.E. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am. J. Pathol. 146 (1995) 20-26
55. Sarela A.I., Macadam R.C.A., Farmery S.M., Markham A.F., and Guillou P.J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46 (2000) 645-650
56. Scalmati A., and Lipkin M. Proliferation and differentiation biomarkers in colorectal mucosa and their application to chemoprevention studies. Environ. Health Perspect. 99 (1993) 169-173
57. Garewal H., Bernstein H., Bernstein C., Sampliner R., and Payne C. Reduced bile acid-induced apoptosis in "normal" colorectal mucosa: a potential biological marker for cancer risk. Cancer Res. 56 (1996) 1480-1483
58. Bernstein C., Bernstein H., Garewal H., Dinning P., Jabi R., Sampliner R.E., McCuskey M.K., Panda M., Roe D.J., L'Heureux L., and Payne C.M. A bile acid-induced apoptosis assay for colon cancer risk and associated quality control studies. Cancer Res. 59 (1999) 2353-2357
59. Bernstein H., Holubec H., Warneke J.A., Garewal H., Earnest D.L., Payne C.M., Roe D.J., Cui H., Jacobson E.L., and Bernstein C. Patchy field defects of apoptosis resistance and dedifferentiation in flat mucosa of colon resections from colon cancer patients. Ann. Surg. Oncol. 9 (2002) 505-517
60. Magnuson B.A., Shirtliff N., and Bird R.P. Resistance of aberrant crypt foci to apoptosis induced by azoxymethane in rats chronically fed cholic acid. Carcinogenesis 15 (1994) 1459-1462
61. Greaves L.C., Preston S.L., Tadrous P.J., Taylor R.W., Barron M.J., Oukrif D., Leedham S.J., Deheragoda M., Sasieni P., Novelli M.R., Jankowski J.A.Z., Turnbull D.M., Wright N.A., and McDonald S.A.C. Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proc. Natl. Acad. Sci. USA 103 (2006) 714-719
62. Meyerhardt J.A., Niedzwiecki D., Hollis D., Saltz L.B., Hu F.B., Mayer R.J., Nelson H., Whittom R., Hantel A., Thomas J., and Fuchs C.S. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 298 (2007) 754-764
63. Bernstein H., Holubec H., Bernstein C., Ignatenko N., Gerner E., Dvorak K., Besselsen D., Ramsey L., Dall'Agnol M., Blohm-Mangone K.A., Padilla-Torres J., Cui H., Garewal H., and Payne C.M. Unique dietary-related mouse model of colitis. Inflamm. Bowel. Dis. 12 (2006) 278-293
64. Brentnall T.A., Crispin D.A., Bronner M.P., Cherian S.P., Hueffed M., Rabinovitch P.S., Rubin C.E., Haggitt R.C., and Boland C.R. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res. 56 (1996) 1237-1240
65. Rabinovitch P.S., Dziadon S., Brentnall T.A., Emond M.J., Crispin D.A., Haggitt R.C., and Bronner M.P. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res. 59 (1999) 5148-5153
66. Issa J.P.J., Ahuja N., Toyota M., Bronner M.P., and Brentnall T.A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 61 (2001) 3573-3577
67. Chen R., Rabinovitch P.S., Crispin D.A., Emond M.J., Bronner M.P., and Brentnall T.A. The initiation of colon cancer in a chronic inflammatory setting. Carcinogenesis 26 (2005) 1513-1519
68. Crowley-Weber C.L., Dvorakova K., Crowley C., Bernstein H., Bernstein C., Garewal H., and Payne C.M. Nicotine increases oxidative stress, activates NF-κB and GRP78, induces apoptosis and sensitizes cells to genotoxic/xenobiotic stresses by a multiple stress inducer, deoxycholate: relevance to colon carcinogenesis. Chem. Biol. Interact. 145 (2003) 53-66
69. Dvorak K., Payne C.M., Chavarria M., Ramsey L., Dvorakova B., Bernstein H., Holubec H., Sampliner R.E., Guy N., Condon A., Bernstein C., Green S.B., Prasad A., and Garewal H.S. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 56 (2007) 763-771